ATC Group: C08CA13 Lercanidipine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C08CA13 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C08 Calcium channel blockers
3 C08C Selective calcium channel blockers with mainly vascular effects
4 C08CA Dihydropyridine derivatives
5 C08CA13 Lercanidipine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 10 mg

Active ingredients in C08CA13

Active Ingredient Description
Lercanidipine

Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.

Related product monographs

Title Information Source Document Type  
ZANIDIP Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Romania (RO)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.